[Federal Register Volume 72, Number 46 (Friday, March 9, 2007)]
[Rules and Regulations]
[Pages 10595-10596]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-4205]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Oxfendazole Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the

[[Page 10596]]

animal drug regulations to reflect approval of a supplemental new 
animal drug application (NADA) filed by Fort Dodge Animal Health, 
Division of Wyeth. The supplemental NADA provides for over-the-counter 
(OTC) marketing status for oral use of oxfendazole suspension in 
cattle.

DATES: This rule is effective March 9, 2007.

FOR FURTHER INFORMATION CONTACT: Joan C. Gotthardt, Center for 
Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-7571, e-mail: 
<a href="/cdn-cgi/l/email-protection#88e2e7e9e6a6efe7fcfce0e9faecfcc8eeece9a6e0e0fba6efe7fe"><span class="__cf_email__" data-cfemail="6802070906460f071c1c00091a0c1c280e0c094600001b460f071e">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: Fort Dodge Animal Health, Division of Wyeth, 
800 Fifth St. NW., Fort Dodge, IA 50501, filed a supplement to NADA 
140-854 for SYNANTHIC (oxfendazole) Bovine Dewormer Suspension, 
approved for oral use in cattle for the removal of various internal 
parasites. The supplemental NADA provides for OTC marketing status. The 
supplemental application is approved as of January 29, 2007, and the 
regulations are amended in 21 CFR 520.1630 to reflect the approval and 
a current format. The basis of approval is discussed in the freedom of 
information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    The agency has determined under 21 CFR 25.33(a)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Parts 520

    Animal drugs.


0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

0
2. Amend Sec.  520.1630 as follows:
0
a. Redesignate paragraph (d) as paragraph (e);
0
b. Add new paragraph (d);
0
c. Revise the introductory text in newly redesignated paragraphs (e)(1) 
and (e)(2); and
0
d. Revise paragraph (a) and newly redesignated paragraphs (e)(1)(i), 
(e)(1)(iii), (e)(2)(i), and (e)(2)(iii).
    The redesignation, addition, and revisions read as follows:


Sec.  520.1630  Oxfendazole suspension.

    (a) Specifications. Each milliliter of suspension contains:
    (1) 90.6 milligrams (mg) oxfendazole (9.06 percent).
    (2) 225.0 mg oxfendazole (22.5 percent).
    (d) Special considerations. See Sec.  500.25 of this chapter. If 
labeled for administration by stomach tube: Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.
    (e) Conditions of use--(1) Horses. Use the product described in 
paragraph (a)(1) of this section as follows:
    (i) Amount. 10 mg per kilogram (/kg) of body weight by stomach tube 
or dose syringe. Horses maintained on premises where reinfection is 
likely to occur should be retreated in 6 to 8 weeks.
    (iii) Limitations. Withholding feed or water prior to use is 
unnecessary. Administer drug with caution to sick or debilitated 
horses. Do not use in horses intended for human consumption.
    (2) Cattle. Use the products described in paragraphs (a)(1) and 
(a)(2) of this section as follows:
    (i) Amount. 4.5 mg/kg of body weight by dose syringe. Treatment may 
be repeated in 4 to 6 weeks.
    (iii) Limitations. Cattle must not be slaughtered until 7 days 
after treatment. Do not use in lactating dairy cattle.

    Dated: February 21, 2007.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary 
Medicine.
[FR Doc. E7-4205 Filed 3-8-07; 8:45 am]
BILLING CODE 4160-01-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>